Allurion Technologies’ (ALUR) Neutral Rating Reiterated at Chardan Capital

Allurion Technologies (NYSE:ALUR)‘s stock had its “neutral” rating restated by investment analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $2.50 price objective on the stock. Chardan Capital’s price target would indicate a potential downside of 21.11% from the company’s current price. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.39) EPS.

Separately, Roth Mkm reissued a “buy” rating and issued a $16.00 price target on shares of Allurion Technologies in a research note on Friday, March 21st.

Allurion Technologies Stock Performance

Shares of Allurion Technologies stock opened at $3.17 on Thursday. The stock’s 50-day simple moving average is $4.02 and its 200 day simple moving average is $9.75. Allurion Technologies has a 52-week low of $2.15 and a 52-week high of $98.75. The stock has a market capitalization of $15.19 million, a P/E ratio of -0.26 and a beta of -0.59.

Allurion Technologies (NYSE:ALUR) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($7.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.00) by ($2.00). The company had revenue of $5.59 million during the quarter, compared to analyst estimates of $5.60 million. Equities research analysts forecast that Allurion Technologies will post -9.96 EPS for the current fiscal year.

Institutional Trading of Allurion Technologies

A hedge fund recently raised its stake in Allurion Technologies stock. Geode Capital Management LLC raised its position in shares of Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the period. Geode Capital Management LLC owned approximately 0.80% of Allurion Technologies worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 21.39% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.